BNTC vs. SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, ADCT, and VNDA
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), ADC Therapeutics (ADCT), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Benitec Biopharma (NASDAQ:BNTC) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 4.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Benitec Biopharma has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Benitec Biopharma has higher revenue and earnings than Silverback Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
Benitec Biopharma received 163 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 63.73% of users gave Benitec Biopharma an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
Benitec Biopharma currently has a consensus target price of $16.00, suggesting a potential upside of 87.13%. Given Benitec Biopharma's higher probable upside, research analysts plainly believe Benitec Biopharma is more favorable than Silverback Therapeutics.
Silverback Therapeutics' return on equity of -29.62% beat Benitec Biopharma's return on equity.
In the previous week, Benitec Biopharma had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Benitec Biopharma and 0 mentions for Silverback Therapeutics. Benitec Biopharma's average media sentiment score of 1.88 beat Silverback Therapeutics' score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the media.
Summary
Benitec Biopharma beats Silverback Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
